OraSure Technologies (NASDAQ:OSUR) Rating Lowered to Hold at StockNews.com

StockNews.com downgraded shares of OraSure Technologies (NASDAQ:OSUR) from a buy rating to a hold rating in a research report report published on Thursday morning.

OraSure Technologies Stock Performance

NASDAQ OSUR opened at $3.89 on Thursday. The firm’s fifty day moving average price is $3.81 and its two-hundred day moving average price is $4.05. The stock has a market cap of $290.16 million, a PE ratio of 25.93 and a beta of 0.05. OraSure Technologies has a fifty-two week low of $3.52 and a fifty-two week high of $8.04.

Institutional Trading of OraSure Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its stake in shares of OraSure Technologies by 23.1% during the fourth quarter. Renaissance Technologies LLC now owns 2,774,443 shares of the medical instruments supplier’s stock worth $10,016,000 after buying an additional 521,400 shares during the last quarter. American Century Companies Inc. grew its stake in shares of OraSure Technologies by 11.4% in the fourth quarter. American Century Companies Inc. now owns 2,345,837 shares of the medical instruments supplier’s stock worth $8,468,000 after purchasing an additional 240,224 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of OraSure Technologies by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 1,844,139 shares of the medical instruments supplier’s stock worth $6,659,000 after purchasing an additional 46,325 shares during the last quarter. Systematic Financial Management LP grew its stake in shares of OraSure Technologies by 14.9% in the third quarter. Systematic Financial Management LP now owns 1,252,112 shares of the medical instruments supplier’s stock worth $5,347,000 after purchasing an additional 162,364 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of OraSure Technologies by 27.2% in the third quarter. BNP Paribas Financial Markets now owns 855,951 shares of the medical instruments supplier’s stock worth $3,655,000 after purchasing an additional 183,191 shares during the last quarter. Institutional investors own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.